Euflexxa is synthetic copy of hyaluronan, a viscous and elastic substance found in normal synovial joint fluid. It is injected directly into the joint to improve joint function and works in the following ways:
Lubrication and shock absorption.
Anti-inflammatory actions.
Analgesic properties.
Stimulates production of normal, non-inflamed joint fluid.
Protects residual cartilage within the joint.
Euflexxa can be used in the knee, hip, ankle and foot, as well as the shoulder, elbow, wrist and base of thumb.
The Treatment
Euflexxa has been shown to have improved efficacy in a non-swollen and less inflamed joint, so it is recommended to have any excess fluid in the joint aspirated and treated with cortisone 2 - 4 weeks prior to commencing Euflexxa. A referral for ultrasound and aspiration of the joint effusion can be included with your Euflexxa referral from your doctor.
The injection is performed under CT guidance and sterile conditions by one of our doctors.
The Euflexxa treatment is a series of 3 injections performed 1 - 2 weeks apart. The length of each appointment is 10 - 15 minutes and patients are able to drive after each injection.
At the first appointment, any excess inflamed joint fluid will be aspirated from the joint via the same needle that will administer the Euflexxa.
Relative rest for 48 hours is recommended after each injection. Where possible, avoid activities that exacerbate or worsen the joint symptoms during that time.
The maximal effect of Euflexxa is seen at 8 weeks after the first injection. Beneficial effects in some patients can extend beyond 6 months and the treatment can be performed twice a year.
Side Effects and Risks
Transient joint swelling or stiffness.
Bruising or mild-moderate temporary pain at the injection site.
Infection is rare. If fever develops with joint pain, swelling, redness and warmth in the week following an injection, you should immediately contact your doctor and our practice.
If you have any other concerns regarding the treatment, please contact our clinic.
Euflexxa is recommended for use in symptomatic osteoarthritis by the International Osteoarthritis Research Society, European League Against Rheumatism, American College of Rheumatology (American Arthritis Foundation) and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
